Home Alzheimer’s Disease Niraparib Maintenance Therapy Shows Promise for Chinese Patients With Platinum-Sensitive, Recurrent Ovarian...

Niraparib Maintenance Therapy Shows Promise for Chinese Patients With Platinum-Sensitive, Recurrent Ovarian Cancer

Data from the randomized, double-blind, placebo-controlled phase 3 NORA trial (NCT03705156) indicated that niraparib (Zejula) maintenance treatment reduced the risk of disease progression or death and prolonged progression-free survival (PFS) in Chinese patients with platinum-sensitive, recurrent ovarian cancer when compared with placebo.1

The study, published in Annals of Oncology, also indicated that an individualized starting dose (ISD) of niraparib based on baseline bodyweight and platelet count could improve the tolerability of niraparib without affecting treatment outcomes, and should therefore be considered standard practice in this patient setting.

“This is the first trial of PARP inhibitor maintenance therapy for ovarian cancer conducted in an Asian patient population and will support a change in clinical practice,” wrote the study authors, who were led by Xiaohua Wu, MD,…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia

Patients treated with PARP inhibitors saw an increased risk of myelodysplastic syndrome and acute myeloid leukemia (AML) versus patients treated with placebo, according to...

Salma Jabbour, MD, on Next Steps for the KEYNOTE-799 Study

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed how she hopes the results of the KEYNOTE-799 study...

Recent Comments